Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Arena Pharmaceuticals (ARNA)

Arena Pharmaceuticals (ARNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,165,283
  • Shares Outstanding, K 61,659
  • Annual Sales, $ 50 K
  • Annual Income, $ -616,430 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 0.55
  • Price/Sales 114,103.41
  • Price/Cash Flow N/A
  • Price/Book 9.14
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -10.13
  • Most Recent Earnings $-2.54 on 02/23/22
  • Next Earnings Date 05/04/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/22
See More
  • Average Estimate -2.32
  • Number of Estimates 2
  • High Estimate -2.27
  • Low Estimate -2.37
  • Prior Year -1.98
  • Growth Rate Est. (year over year) -17.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
92.85 +7.69%
on 02/22/22
100.00 -0.01%
on 03/10/22
+5.99 (+6.37%)
since 02/10/22
3-Month
89.03 +12.31%
on 01/25/22
100.00 -0.01%
on 03/10/22
+50.05 (+100.22%)
since 12/10/21
52-Week
45.50 +119.76%
on 08/19/21
100.00 -0.01%
on 03/10/22
+26.20 (+35.51%)
since 03/10/21

Most Recent Stories

More News
Arena Pharmaceuticals Inc. (ARNA) Climbs to Annual-High Share Price

Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded today at a new 12-month high of $100.00. Approximately 748,000 shares have changed hands today, as compared to an average 30-day volume of 1.4 million shares....

ARNA : 99.99 (+0.06%)
Pre-Market Brief: Stocks Give Up Overnight Gains as the U.S. Will Ban Russian Energy Exports

Morning Markets March S&P 500 futures this morning gave up an overnight rally and are down by -0.18%. Stocks indexes retreated this morning as crude prices jumped more than +4% after Bloomberg reported...

BAC : 47.00 (+1.16%)
MT : 25.11 (-0.71%)
ARNA : 99.99 (+0.06%)
CLAR : 4.51 (+2.97%)
NINE : 1.4500 (+15.08%)
MASS : 2.56 (-6.57%)
ROVR : 10.99 (unch)
TDUP : 1.5500 (+15.67%)
Arena Reports Fourth Quarter and Full Year 2021 Financial Results and Key Program Updates

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2021.

ARNA : 99.99 (+0.06%)
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Compensation Committee of its Board of Directors granted to 18 new employees 18,527 inducement restricted stock units ("RSUs"). The...

ARNA : 99.99 (+0.06%)
Why Investors Aren't Worried About Pfizer's Latest Failure

Is this discontinued drug from Pfizer nothing more than a drop in the bucket?

PFE : 25.65 (+2.07%)
IONS : 34.01 (+0.21%)
TRIL : 18.44 (+2.62%)
ARNA : 99.99 (+0.06%)
Arena Pharmaceuticals to Release Fourth Quarter and Full-Year 2021 Financial Results and Provide Corporate Update on February 23

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its fourth quarter and full-year 2021 financial results and provide a corporate update on Wednesday, February 23, 2022, after the close of the U.S....

ARNA : 99.99 (+0.06%)
3 Clinical Trials to Watch in the First Half of 2022

These clinical studies don't just impact the companies conducting them.

ARNA : 99.99 (+0.06%)
PFE : 25.65 (+2.07%)
RHHBY : 35.4400 (+0.43%)
BIIB : 157.90 (-0.07%)
ABBV : 176.95 (+3.04%)
VRTX : 450.97 (+0.13%)
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Compensation Committee of its Board of Directors granted inducement restricted stock units ("RSUs") to new employees. The inducement...

ARNA : 99.99 (+0.06%)
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Compensation Committee of its Board of Directors granted to 16 new employees 28,659 inducement restricted stock units ("RSUs"). The...

ARNA : 99.99 (+0.06%)
Harley-Davidson, Arena rise; Capital One, Carnival fall

NEW YORK (AP) — Stocks that traded heavily or had substantial price changes Monday:

HOG : 33.55 (+2.19%)
BMY : 58.87 (+1.10%)
ARNA : 99.99 (+0.06%)
IGMS : 8.89 (unch)
LLY : 748.01 (-0.25%)
CCL : 24.90 (-1.78%)
PFE : 25.65 (+2.07%)
BAX : 33.21 (+0.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Arena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs. BELVIQ (lorcaserin HCl), their internally discovered drug for chronic weight management, is their...

See More

Key Turning Points

3rd Resistance Point 100.03
2nd Resistance Point 100.02
1st Resistance Point 100.00
Last Price 99.99
1st Support Level 99.97
2nd Support Level 99.96
3rd Support Level 99.94

See More

52-Week High 100.00
Last Price 99.99
Fibonacci 61.8% 79.18
Fibonacci 50% 72.75
Fibonacci 38.2% 66.32
52-Week Low 45.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar